Vifor Pharma AG Valuation
| GNHAYDelisted Stock | USD 38.39 0.00 0.00% |
At this time, the company appears to be overvalued. Vifor Pharma AG has a current Real Value of $31.29 per share. The regular price of the company is $38.39. Our model measures the value of Vifor Pharma AG from inspecting the company fundamentals such as Return On Equity of 0.0665, shares outstanding of 324.46 M, and Operating Margin of 0.21 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Vifor Pharma's price fluctuation is very steady at this time. Calculation of the real value of Vifor Pharma AG is based on 3 months time horizon. Increasing Vifor Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Vifor Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vifor Pink Sheet. However, Vifor Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 38.39 | Real 31.29 | Hype 38.39 |
The intrinsic value of Vifor Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vifor Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vifor Pharma AG helps investors to forecast how Vifor pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vifor Pharma more accurately as focusing exclusively on Vifor Pharma's fundamentals will not take into account other important factors: Vifor Pharma Total Value Analysis
Vifor Pharma AG is currently forecasted to have takeover price of 10.99 B with market capitalization of 12.45 B, debt of 75 M, and cash on hands of 993.6 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Vifor Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.99 B | 12.45 B | 75 M | 993.6 M |
Vifor Pharma Investor Information
The book value of the company was currently reported as 10.76. The company last dividend was issued on the 12th of May 2022. Based on the key measurements obtained from Vifor Pharma's financial statements, Vifor Pharma AG is not in a good financial situation at this time. It has a very high probability of going through financial hardship in October.Vifor Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vifor Pharma has an asset utilization ratio of 35.78 percent. This suggests that the Company is making $0.36 for each dollar of assets. An increasing asset utilization means that Vifor Pharma AG is more efficient with each dollar of assets it utilizes for everyday operations.Vifor Pharma Profitability Analysis
The company reported the revenue of 1.82 B. Net Income was 144.4 M with profit before overhead, payroll, taxes, and interest of 1.14 B.About Vifor Pharma Valuation
Our relative valuation model uses a comparative analysis of Vifor Pharma. We calculate exposure to Vifor Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vifor Pharma's related companies.Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. As of August 9, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG. VIFOR PHARMA is traded on OTC Exchange in the United States.
8 Steps to conduct Vifor Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Vifor Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Vifor Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Vifor Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Vifor Pharma's revenue streams: Identify Vifor Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Vifor Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Vifor Pharma's growth potential: Evaluate Vifor Pharma's management, business model, and growth potential.
- Determine Vifor Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Vifor Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Vifor Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 325.1 M | |
| Quarterly Earnings Growth Y O Y | 0.837 | |
| Forward Price Earnings | 18.6916 | |
| Retained Earnings | 3.8 B |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Vifor Pink Sheet
If you are still planning to invest in Vifor Pharma AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vifor Pharma's history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |